Hiromichi Suzuki

Hiromichi Suzuki

Auto-generated profile, based on publicly available information

Hiromichi Suzuki

Department of Infectious Diseases, University of Tsukuba Hospital, Tsukuba, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
HSHiromichi Suzuki
Hiromichi Suzuki
SHShigemi Hitomi
Shigemi Hitomi
YYYuji Yaguchi
Yuji Yaguchi
KTKiyoko Tamai
Kiyoko Tamai
AUAtsuo Ueda
Atsuo Ueda
KYKatsunori Yanagihara
Katsunori Yanagihara
The Verigene Gram-positive blood culture test (BC-GP) and the Verigene Gram-negative blood culture test (BC-GN) identify representative Gram-positive bacteria, Gram-negative bacteria and their antimicrobial resistance by detecting resistance genes within 3 h. Significant benefits are anticipated due to their rapidity and accuracy, however, their clinical utility is unproven in clinical studies. We performed a clinical trial between July 2014 and December 2014 for hospitalized bacteremia patients. During the intervention period (N = 88), Verigene BC-GP and BC-GN was used along with conventional microbiological diagnostic methods, while comparing the clinical data and outcomes with those during the control period (N = 147) (UMIN registration ID: UMIN000014399). The median duration between the initiation of blood culture incubation and the reporting time of the Verigene system results was 21.7 h (IQR 18.2-26.8) and the results were found in 88% of the cases by the next day after blood cultures were obtained without discordance. The hospital-onset infection rate was higher in the control period (24% vs. 44%, p = 0.002), however, no differences were seen in co-morbidities and severity between the control and intervention periods. During the intervention period, the time of appropriate antimicrobial agents' initiation was significantly earlier than that in the control period (p = 0.001) and most cases (90%; 79/88) were treated with antimicrobial agents with in-vitro susceptibility for causative bacteria the day after the blood culture was obtained. The costs for antimicrobial agents were lower in the intervention period (3618 yen vs. 8505 yen, p = 0.001). The 30-day mortality was lower in the intervention period (3% vs. 13%, p = 0.019).

1 June 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
YTYuto Takeuchi
Yuto Takeuchi
YAYusaku Akashi
Yusaku Akashi
DKDaisuke Kato
Daisuke Kato
MKMiwa Kuwahara
Miwa Kuwahara
SMShino Muramatsu
Shino Muramatsu
HSHiromichi Suzuki
Hiromichi Suzuki
Several antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed worldwide, but their clinical utility has not been well established. In this study, we evaluated the analytical and clinical performance of QuickNavi™-COVID19 Ag, a newly developed antigen test in Japan. This prospective observational study was conducted at a PCR center between October 7 and December 5, 2020. The included patients were referred from a local public health center and 89 primary care facilities. We simultaneously obtained two nasopharyngeal samples with flocked swabs; one was used for the antigen test and the other for real-time reverse transcription PCR (RT-PCR). Using the results of real-time RT-PCR as a reference, the performance of the antigen test was evaluated. A total of 1186 patients were included in this study, and the real-time RT-PCR detected SARS-CoV-2 in 105 (8.9%). Of these 105 patients, 33 (31.4%) were asymptomatic. The antigen test provided a 98.8% (95% confidence interval [CI]: 98.0%–99.4%) concordance rate with real-time RT-PCR, along with a sensitivity of 86.7% (95% CI: 78.6%–92.5%) and a specificity of 100% (95% CI: 99.7%–100%). False-negatives were observed in 14 patients, 8 of whom were asymptomatic and had a low viral load (cycle threshold (Ct) > 30). In symptomatic patients, the sensitivity was 91.7% (95% CI: 82.7%–96.9%). QuickNavi™-COVID19 Ag showed high specificity and sufficient sensitivity for the detection of SARS-CoV-2. This test is a promising potential diagnostic modality especially in symptomatic patients.

11 August 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
STSho Tashiro
Sho Tashiro
TMTakayuki Mihara
Takayuki Mihara
MSMoe Sasaki
Moe Sasaki
CSChiaki Shimamura
Chiaki Shimamura
RSRina Shimamura
Rina Shimamura
HKHiroyuki Kunishima
Hiroyuki Kunishima

1 March 1991 in The Lancet
Verified
Journal Article
Closed access
KHKeiichi Hishikawa
Keiichi Hishikawa
TNToshio Nakaki
Toshio Nakaki
HSHiromichi Suzuki
Hiromichi Suzuki
TSTakao Saruta
Takao Saruta
RKRyuichi Kato
Ryuichi Kato

1 November 2018 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YIYuki Igarashi
Yuki Igarashi
STSho Tashiro
Sho Tashiro
YEYuki Enoki
Yuki Enoki
KTKazuaki Taguchi
Kazuaki Taguchi
KMKazuaki Matsumoto
Kazuaki Matsumoto
HKHiroyuki Kunishima
Hiroyuki Kunishima

1 December 2020 in Journal of Medical Microbiology
Verified
Journal Article
Open access
YMYoshitomo Morinaga
Yoshitomo Morinaga
HSHiromichi Suzuki
Hiromichi Suzuki
SNShigeyuki Notake
Shigeyuki Notake
TMTakashi Mizusaka
Takashi Mizusaka
KUKeiichi Uemura
Keiichi Uemura
KYKatsunori Yanagihara
Katsunori Yanagihara
Introduction. Resistance against macrolide antibiotics in Mycoplasma pneumoniae is becoming non-negligible in terms of both appropriate therapy and diagnostic stewardship. Molecular methods have attractive features for the identification of Mycoplasma pneumoniae as well as its resistance-associated mutations of 23S ribosomal RNA (rRNA). Hypothesis/Gap Statement. The automated molecular diagnostic sytem can identify macrolide-resistant M. pneumoniae . Aim. To assess the performance of an automated molecular diagnostic system, GENECUBE Mycoplasma, in the detection of macrolide resistance-associated mutations. Methodology. To evaluate whether the system can distinguish mutant from wild-type 23S rRNA, synthetic oligonucleotides mimicking known mutations (high-level macrolide resistance, mutation in positions 2063 and 2064; low-level macrolide resistance, mutation in position 2067) were assayed. To evaluate clinical oropharyngeal samples, purified nucleic acids were obtained from M. pneumoniae -positive samples by using the GENECUBE system from nine hospitals. After confirmation by re-evaluation of M. pneumoniae positivity, Sanger-based sequencing of 23S rRNA and mutant typing using GENECUBE Mycoplasma were performed. Results. The system reproducibly identified all synthetic oligonucleotides associated with high-level macrolide resistance. Detection errors were only observed for A2067G (in 2 of the 10 measurements). The point mutation in 23S rRNA was detected in 67 (26.9 %) of 249 confirmed M. pneumoniae -positive clinical samples. The mutations at positions 2063, 2064 and 2617 were observed in 65 (97.0 %), 2 (3.0 %) and 0 (0.0 %) of the 67 samples, respectively. The mutations at positions 2063 and 2064 were A2063G and A2064G, respectively. The results from mutant typing using GENECUBE Mycoplasma were in full agreement with the results from sequence-based typing. Conclusion. GENECUBE Mycoplasma is a reliable test for the identification of clinically significant macrolide-resistant M. pneumoniae .